Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

IntroductionPreviously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations.MethodsPatients were identified from a prospective database developed by Boehringer...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Keunchil Park, Antonio Passaro, Filippo De Marinis, Flavio Solca, Angela Märten, Edward S. Kim
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Subjects:	afatinib non-small-cell lung cancer uncommon EGFR mutations compound mutations EGFR exon 20 insertions
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.834704/full

Similar Items

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
by: Wei Dong, et al.
Published: (2022-11-01)

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report
by: Petros Christopoulos, et al.
Published: (2024-05-01)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
by: Tomomi Masuda, et al.
Published: (2020-08-01)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
by: Liping Kang, et al.
Published: (2023-02-01)

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
by: Yue Hao, et al.
Published: (2023-08-01)

Clinical Outcomes of Later‐Generation EGFR‐TKIs for Uncommon EGFR Mutations in NSCLC: A Multicenter Real‐World Study
by: Lisa Shigematsu, et al.
Published: (2025-10-01)

Uncommon <i>EGFR</i> Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
by: Ilaria Attili, et al.
Published: (2022-01-01)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
by: Chen Shi, et al.
Published: (2023-06-01)

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
by: Chen Liao, et al.
Published: (2025-01-01)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR‐mutated NSCLC treated with afatinib
by: Chen‐Te Wu, et al.
Published: (2023-09-01)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
by: Yingying Jiang, et al.
Published: (2023-05-01)

Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
by: Han X, et al.
Published: (2024-11-01)

Experience of Uncommon EGFR Mutation in Lung Scheme Quality Program: Discussing Risks and Opportunities for the Improvement of Laboratory Response
by: Alessandro Pancrazzi, et al.
Published: (2021-07-01)

“ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834)
by: Luo FX, et al.
Published: (2024-05-01)

Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
by: Jerry Shu-Hung Kuo, et al.
Published: (2025-01-01)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
by: Hyun Ae Jung, et al.
Published: (2020-10-01)

Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report
by: Pascal Wang, et al.
Published: (2022-07-01)

Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
by: Alexander Meisel
Published: (2020-03-01)

Responsive afatinib treatment in high-grade salivary gland ductal carcinoma and NSCLC with uncommon EGFR mutations: Treatment outcomes
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
by: Ikei S. Kobayashi, et al.
Published: (2021-12-01)

Advanced lung adenocarcinoma harboring uncommon EGFR 19 Del and T790M/trans-C797S mutations after resistance: a case report and literature review
by: Yuting Xiao, et al.
Published: (2025-04-01)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
by: Xingxiang Pu, et al.
Published: (2023-10-01)

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01)

Real-world progression-free survival of first line afatinib patients with EGFR-mutant advanced lung adenocarcinoma: A multicentre study in Indonesia
by: Noni Novisari Soeroso, et al.
Published: (2025-01-01)

Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib
by: Hisanori Hirokawa, et al.
Published: (2024-01-01)

Afatinib: new treatment options for lung cancer with activating EGFR mutations
by: M. V. Stepanchenko, et al.
Published: (2015-12-01)

Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations
by: Yueming He, et al.
Published: (2024-11-01)

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets
by: Santiago Viteri, et al.
Published: (2023-02-01)

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
by: Masaki Kanazu, et al.
Published: (2021-01-01)

Case of a rare EGFR mutation L747P identified using the lung cancer compact Panel™ leading to successful Afatinib treatment
by: Hitoshi Sumitani, et al.
Published: (2025-01-01)

Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report
by: Caijiu Deng, et al.
Published: (2025-04-01)

Survival Outcomes in EGFR‐Mutant Non‐Small Cell Lung Cancer With Brain Metastases: Kaplan–Meier and Cox Regression Analyses Across Treatment Stages
by: Haoran Qi, et al.
Published: (2025-05-01)

Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries
by: Zulkifli Amin, et al.
Published: (2017-05-01)

Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries
by: Zulkifli Amin, et al.
Published: (2017-05-01)

Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
by: Xue YANG, et al.
Published: (2022-05-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
by: Meiyi XU, et al.
Published: (2023-02-01)

A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
by: Cam Phuong Pham, et al.
Published: (2024-02-01)

THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION
by: К. К. LAKTIONOV, et al.
Published: (2016-12-01)

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
by: Arsela Prelaj, et al.
Published: (2022-06-01)

Case Report: A Bilateral Synchronous Primary Non‐Small Cell Lung Cancer Patient With Two Different EGFR Mutations
by: Thanh‐Dung Quach, et al.
Published: (2025-08-01)